Skin diseases
26 public biotech companies we cover are developing treatments for atopic dermatitis, psoriasis, hidradenitis suppurativa, alopecia, wounds and other skin conditions. 21 upcoming catalysts are listed below, with dates as the companies gave them.
Companies
- AbCellera Biologics (ABCL)Thesis Intact
Atopic dermatitis
- Abeona Therapeutics (ABEO)Thesis Intact
Recessive dystrophic epidermolysis bullosa
- Aclaris Therapeutics (ACRS)Thesis Intact
Lichen planus, Atopic dermatitis
- Alumis (ALMS)Thesis Challenged
Plaque psoriasis, Cutaneous lupus erythematosus, Moderate-to-severe plaque psoriasis
- Aquestive Therapeutics (AQST)Thesis Challenged
Alopecia areata, Atopic dermatitis, Androgenic alopecia
- Arcus Biosciences (RCUS)Thesis Intact
Psoriasis, Atopic dermatitis, Chronic spontaneous urticaria, Atopic dermatitis and chronic spontaneous urticaria
- Avalo Therapeutics (AVTX)Thesis Intact
Hidradenitis suppurativa
- Bolt Biotherapeutics (BOLT)Thesis Broken
Atopic dermatitis
- Cabaletta Bio (CABA)Thesis Intact
Pemphigus vulgaris
- Corvus Pharmaceuticals (CRVS)Thesis Intact
Atopic dermatitis, Hidradenitis suppurativa
- Immunocore (IMCR)Thesis Intact
Atopic dermatitis
- InflaRx (IFRX)Thesis Intact
Hidradenitis suppurativa, Chronic spontaneous urticaria
- INmune Bio (INMB)Thesis Challenged
Recessive dystrophic epidermolysis bullosa
- MediWound (MDWD)Thesis Challenged
Thermal burns, Pressure ulcers, Venous leg ulcers
- Monte Rosa Therapeutics (GLUE)Thesis Intact
Hidradenitis suppurativa
- MoonLake Immunotherapeutics (MLTX)Thesis Intact
Hidradenitis suppurativa
- Nektar Therapeutics (NKTR)Thesis Intact
Alopecia areata, Atopic dermatitis
- NextCure (NXTC)Thesis Broken
Moderate-to-severe plaque psoriasis
- Palvella Therapeutics (PVLA)Thesis Intact
Angiokeratomas, Serious rare skin disease, Additional rare skin diseases, Cutaneous venous malformations, and 2 more
- Q32 Bio (QTTB)Thesis Intact
Alopecia areata, Atopic dermatitis
- Quoin Pharmaceuticals (QNRX)Thesis Intact
Angiofibromas, Peeling Skin Syndrome, Pachyonychia congenita
- Roivant Sciences (ROIV)Thesis Intact
Lichen planopilaris, Cutaneous sarcoidosis, Cutaneous lupus erythematosus
- Sagimet Biosciences (SGMT)Thesis Intact
Acne vulgaris, Moderate-to-severe acne vulgaris
- Shattuck Labs (STTK)Thesis Intact
Hidradenitis suppurativa
- Soligenix (SNGX)Thesis Broken
Psoriasis
- Zura Bio (ZURA)Thesis Intact
Hidradenitis suppurativa
Drug pages
Upcoming catalysts
Estimated timing · a month, quarter, half-year or year-end the company gave
Expected in October 2026
- October 2026SL-325 · IND submission · Hidradenitis suppurativa · moderate to severe
Expected in Q4 2026
- Q4 2026ABCL575 · Phase 1 results · Atopic dermatitis · moderate to severe
- Q4 2026Bosakitug · Phase 2 topline results · Atopic dermatitis · moderate to severe
- Q4 2026Modzatinib · Phase 2b start · Lichen planus
- Q4 2026Envudeucitinib · NDA submission · Moderate-to-severe plaque psoriasis
- Q4 2026EscharEx · Trial start · Pressure ulcers
- Q4 2026Sonelokimab · BLA accepted for review · Hidradenitis suppurativa
- Q4 2026QTORIN pitavastatin · Phase 2 start · Disseminated superficial actinic porokeratosis
- Q4 2026QTORIN rapamycin · Phase 3 start · Cutaneous venous malformations
- Q4 2026Tibulizumab · Phase 2 results (TibuSHIELD) · Hidradenitis suppurativa · moderate to severe
Expected in H2 2026
- H2 2026ATI-052 · Phase 1b topline results · Atopic dermatitis
- H2 2026IMC-U120AI · CTA submission · Atopic dermatitis
- H2 2026IMVT-1402 · Phase 2 topline results · Cutaneous lupus erythematosus
Expected by end of 2026
- end of 2026TVB-3567 · Phase 2 start · Acne vulgaris · moderate-to-severe
Expected in Q1 2027
- Q1 2027EscharEx · Phase 3 enrollment complete (VALUE) · Venous leg ulcers
Expected by end of March 2027
- early 2027AVR-001 · Phase 2b start · Moderate-to-severe plaque psoriasis
Expected in H1 2027
- H1 2027Abdakibart · Phase 3 start (LOTUS) · Hidradenitis suppurativa
- H1 2027AVTX-010 · IND submission · Hidradenitis suppurativa · additional inflammatory disorders
- H1 2027MRT-8102 · Phase 2 start (GALAXY-1) · Hidradenitis suppurativa · moderate to severe
- H1 2027Bempikibart · Trial start · Alopecia areata · severe to very severe
Expected by end of June 2027
- Mid-2027AB102 · Results · Atopic dermatitis · chronic spontaneous urticaria